作者: A. Karolina Palucka , Hideki Ueno , Joseph W. Fay , Jacques Banchereau
DOI: 10.1111/J.1600-065X.2007.00575.X
关键词:
摘要: Immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit. It can be passive, i.e. transfer of effector cells (T cells) or proteins (antibodies), active, vaccination. In cancer, passive immunotherapy lead some objective clinical responses, thus demonstrating that the reject tumors. However, is not expected yield long-lived memory T might control tumor outgrowth. Active with dendritic cell (DC)-based vaccines has potential induce both tumor-specific and cells. Early trials testing vaccination ex vivo-generated DCs pulsed antigens provide proof-of-principle immunity elicited. Yet, there need improve their efficacy. The next generation DC generate large numbers high-avidity CD8(+) overcome regulatory Therapeutic protocols will combine improved vivo therapies offset suppressive environment established by